BEGIN YOUR JOURNEY TOWARDS PREVENTING CRYPTOGENIC STROKE
If you’ve had a stroke due to an unknown cause, learn how you may be able to prevent another with the Amplatzer™ PFO Occluder.
The Amplatzer™ PFO Occluder, the leading PFO closure device, demonstrated excellent safety and efficacy in reducing the risk of recurrent stroke in the largest PFO trial ever conducted.
The RESPECT trial is the largest clinical trial evaluating patent foramen ovale (PFO) closure.
The trial spanned 13 years, collecting over 5,810 patient-years of data.
The Amplatzer™ PFO Occluder significantly lowers the risk of recurrent ischemic stroke.
The results of the landmark RESPECT trial—a rigorous trial evaluating PFO occlusion—were published in the September 14, 2017 issue of the New England Journal of Medicine.
The landmark RESPECT trial is the largest trial with the most extensive patient follow-up of any trial conducted on PFO closure and the prevention of recurrent ischemic stroke.
* Technical success = Successful delivery and release of the device.
** Procedural success = Successful implant of the device with no in-hospital serious adverse events.
Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.